Policies

POLICIES AND CLINICAL GUIDELINES

CarepathRx policies and procedures provide our nursing partners with the strategy and guidelines needed to establish safe and effective infusion therapy in the home setting.

A. GENERAL

Flushing Catheters NUR-001
Infusion Administration Best Practice Guidelines NUR-002
IV Catheter Care – Quick Reference NUR-003
Blood Culture Collection NUR-004
Drug Level Drawing Times NUR-005
Lab Draw Protocol NUR-006
Antimicrobial Lock Therapy Central Venous Access Device NUR-010
Management of Allergic/Anaphylactic Reactions NUR-012
IV Push Medication via Syringe NUR-013
Withdrawing Medication from a Vial NUR-014
Administration of Cathflo Activase in Adult Patient NUR-015
Aseptic Non-Touch Technique (ANTT) NUR-016
Algorithm for Notification of Pharmacist and Provider NUR-021
Infiltration and Phlebitis NUR-121

Antibiotics

Anti-infective Therapy Guidelines NUR-200

Chemotherapy and Biotherapy

Guidelines NUR-202
Administration via Central Line NUR-203
Administration via Peripheral Line NUR-204
Administration via Bolus Infusion NUR-205
Exposure or Spill NUR-206
Management of Extravasation NUR-207
Vesicants and Vascular Access Recommendations NUR-208

Nutritional Support/Fluid Support

Guidelines NUR-209
Enteral Feedings: Gravity Controlled & Pump Assisted NUR-210
Gastrostomy and Jejunostomy Care NUR-212
Hydration Therapy NUR-213

Pain Management

Pain Management Guidelines NUR-216

Cardiac Infusions

Cardiac Inotropic Agents Guidelines NUR-217

B. CATHETERS

Peripheral Vein Catheter/Needle

Guidelines NUR-100
Insertion and Removal NUR-102

Peripherally Inserted Central Catheter (PICC) and Midline Catheter

Guidelines NUR-105
PICC and MIDLINE Catheter Removal NUR-107

Central Venous Catheter (CVC)

Guidelines NUR-108
Vascular Access Device Dressing and Needleless Connector Change NUR-109

Vascular Access Port (VAP)

Non-Coring Needle Insertion, Removal and Dressing Change NUR-113

Pheresis Catheters

Guidelines NUR-120

C. OTHER ADMINISTRATION ROUTES

Continuous Subcutaneous Infusions NUR-007
Subcutaneous Injections NUR-008
Intramuscular Injections NUR-009
Synchromed Pump: Accessing and Refilling Spinal Pumps NUR-011

D. CLINICAL GUIDELINES

Eculizumab (Soliris) and Ravulizumab (Ultomiris) Clinical Guideline for Home Intravenous Therapy CG-001
Belimumab (Benlysta) Clinical Guideline for Home Intravenous Therapy CG-002
Rozanolixizumab (Rystiggo) Clinical Guideline for Home Intravenous Therapy CG-003
Enjaymo (sutimlimab-jome) Clinical Guideline for Home Intravenous Therapy CG-004
Vedolizumab (Entyvio) Guideline for Home Intravenous Therapy CG-005
Eptinezumab-jjmr (Vyepti) Clinical Guideline for Home Intravenous Therapy CG-006
Ustekinumab (Stelara) Clinical Guideline for Home Intravenous Therapy CG-007
Efgartigimod alfa-fcab (Vyvgart)/Efgartigimod alfa and Hyaluronidase-qvfc (Vyvgart Hytrulo) Clinical Guideline for Home Intravenous and Subcutaneous Therapy CG-008
Cinqair (Reslizumab) Clinical Guideline CG-010
Infliximab (Remicade) and Biosimilars Clinical Guideline for Home Intravenous Therapy CG-011
Mirikizumab-mrkz (Omvoh) Clinical Guideline for Home Intravenous Therapy CG-012
Fecal Microbiota Live (Rebyota) Clinical Guideline for Home Administration CG-013
Risankizumab (Skyrizi-rzaa) Clinical Guideline for Home Intravenous Therapy CG-014
Bezlotoxumab (Zinplava) Clinical Guideline for Home Intravenous Therapy CG-015
Guselkumab (Tremfya) Clinical Guideline CG-016
Pemivibart (Pemgarda) Clinical Guideline for Home Intravenous Therapy CG-017
Teprotumumab-trbw (Tepezza) Clinical Guideline for Home Intravenous Therapy CG019
Ocrelizumab (Ocrevus) for Home Infusion Therapy and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo) for Home Subcutaneous Infusion CG020
Intravenous Albumin Administration NUR-222
Subcutaneous Hyqvia Infusion NUR-223
Clinical Guidelines for Outpatient R-EPOCH for Non-Hodgkins Lymphoma NUR-226
Clinical Guidelines for Intravenous Infliximab and Biosimilars NUR-227
Clinical Guidelines for Intravenous Trogarzo (Ibalizumab-uiyk) NUR-228
Guidelines for Outpatient Tepezza (Teprotumumab) Therapy NUR-229
Clinical Guidelines for Belimumab – Benlysta Injection NUR-231
Clinical Guidelines for Intravenous Anifrolumab-FNIA (Saphnelo) NUR-232
Guidelines for Outpatient Ocrelizumab (Ocrevus) Therapy NUR-233
Guidelines for Outpatient Krystexxa (Pegloticase) Therapy NUR-234
Clinical Guideline for Belatecept (Nulojix) NUR-235
Guidelines for Outpatient Blinatuomab NUR-236
Guidelines for Outpatient Abatacept (Orencia) NUR-238
Guidelines for Outpatient IV Yondelis (Trabectedin) NUR-240
Guidelines for Outpatient Intravenous Immune Globulin Therapy NUR-241
Guidelines for Outpatient Fulvestrant (Faslodex) IM Therapy NUR-243
Guidelines for Outpatient Subcutaneous Trastuzumab Hyaluronidase-Oysk (Hereptin Hylecta) NUR-244
Clinical Guideline for Outpatient Enzyme Replacement Therapy NUR-246
Guidelines for Outpatient IV Actemra (Tocilizumab) NUR-247
Guidelines for SC Pertuzumab-Traztuzumab-Hyaluronidase-ZZXF (Phesgo) NUR-248
Guideline for IV Simpopni Aria (Globimumab) Therapy NUR-250
Clinical Guidelines for IV Remdesivir for Treatment of COVID-19 in Outpatient Setting NUR-251
Guidelines for Outpatient IV Uplizna (Inebilizumab-cdon) Therapy NUR-252
Guidelines for Outpatient IV Keytruda (Pembrolizumab) NUR-253
Clinical Guidelines for IV Patisiran (Onpattro) NUR-254
Guidelines for IV Edaravone (Radicava) NUR-255
Guideline for Outpatient IV Alpha-1 Proteinase Inhibitors NUR-256
Guideline for Crizanlizumab-TMCA (Adakveo) NUR-257
Guideline for Outpatient IV Teplizumab (Tzield) NUR-258
Guideline for Outpatient Rituxan (Rituximab) and its Biosimilars Therapy NUR-259
Guidelines for Intravenous Amyloid Beta-Directed Therapies NUR-260
Guidelines for Outpatient Gazyva (Obinutuzumab) NUR-261
Guidelines for In-Home Intravenous Natalizumab (Tysabri) Therapy NUR-262
Guidelines for In-Home Intravenous Vyvgart Therapy NUR-263
Guidelines for In-Home Intravenous Spesolimab-sbzo (Spevigo) Therapy NUR-264

E. INVOICE RESOURCES

Invoice Listing by Pharmacy

These Clinical Guidelines have been created by CarepathRx solely for its internal use and the use of its contracted clinical partners. All other use of these guidelines is prohibited without express written permission. Published as Clinical Guidelines, CarepathRx’s clinical partners may adopt these as policies subject to the partner’s policy adoption processes.

These Clinical Guidelines have been created using resources that were current as of the “Reviewed” date, noted at the beginning of the document. Clinicians should refer to the manufacturer’s Prescribing Information (or equivalent) for the most up-to-date information. While CarepathRx has published these Clinical Guidelines after a close review of available literature and a clinical review process, given the evolving nature and complexity of modern pharmaceutical products, CarepathRx does not and cannot warrant or guarantee that these Clinical Guidelines reflect the objectively best or highest standard of care at any given time.

Nothing within these Clinical Guidelines is intended to supersede or interfere with any individual clinician’s decision-making or professional judgment with respect to either (1) prescribing or dispensing the drug or product in question or (2) the overall treatment plan for an individual patient.